Compare ADMA Biologics Inc (ADMA) vs Aehr Test Systems (AEHR) Price & Performance

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

AEHR Test Systems trades at $103.07, up 3.34% with strong technical momentum and bullish moving average signals. The company shows improving earnings trends with three consecutive quarterly beats, though profitability remains negative with a -14.25% net margin. Recent news highlights significant silicon photonics orders and a strategic pivot toward AI infrastructure, driving investor optimism despite insider selling activity.

Outlook remains growth-focused with FY27 revenue guidance of 160-200% expansion, though high valuation (P/S 65.13) and customer concentration pose risks. Analyst consensus leans neutral with 33% buy ratings, while technical indicators suggest near-term support at $97 with resistance at $107. The stock's AI-driven backlog expansion supports bullish sentiment despite current negative cash flow.